The auction results provide a clear cash value floor for the Chapter 11 estate, but equity recovery remains highly uncertain and dependent on Court approval and distribution plan. Monitor the Bankruptcy Court sale hearings expected in Q3 2026 and any further bids for remaining assets (ST-503, hemophilia A gene therapy, T-Reg platform) which could alter total recoverable value.
Price Chart
Executive Summary
Sangamo Therapeutics, in Chapter 11, completed a Section 363 asset auction, selecting winning bids from PTC Therapeutics ($111M cash + up to $100M milestones for Fabry program) and Eli Lilly ($50M cash for platforms/prion program), plus $2.55M for tools, totaling ~$163.55M cash at closing. The sales require Bankruptcy Court approval and HSR clearance, with Lilly closing expected ~Sept 4, 2026. This monetization provides a cash floor for the estate but leaves equity holders with uncertain recovery given the Chapter 11 process and ongoing solicitation for remaining assets.
Key Facts
- Sangamo selected winning bids from PTC Therapeutics ($111M cash + up to $100M milestones) for Fabry program isaralgagene civaparvovec and Eli Lilly ($50M cash) for capsid delivery, zinc finger, MINT platforms and prion program ST-506.
- Additional $2.55M cash from sale of tools and equipment; total cash consideration at closing ~$163.55M.
- Proposed sales subject to final Bankruptcy Court approval, HSR clearance, and customary closing conditions; Lilly closing expected on or about Sept 4, 2026.
- Sangamo continues to solicit offers for remaining assets: ST-503 (chronic neuropathic pain), giroctocogene fitelparvovec (hemophilia A), and cell therapy/T-Reg assets.
- Company filed for Chapter 11 on June 23, 2026; stock delisted from Nasdaq on May 5, 2026, now trades OTC under SGMOQ.
Financial Impact
~$163.55M cash at closing from asset sales, plus up to $100M in potential milestone payments from PTC Therapeutics
Risk Factors
- Bankruptcy Court may not approve the sales on proposed terms or at all
- HSR review could delay or block the PTC Therapeutics transaction
- Milestone payments (up to $100M) are contingent on FDA approval and may never be received
- Remaining assets (ST-503, hemophilia A, cell therapy) may not attract buyers or may sell for less than expected
- Equity holders likely receive little to no distribution given Chapter 11 priority waterfall
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-347524 |
| Document: d125617dex991.htm | 0001193125-26-347524 |
| Document: 0001193125-26-347524-index-headers.html | 0001193125-26-347524 |
| Document: 0001193125-26-347524-index.html | 0001193125-26-347524 |
| Document: 0001193125-26-347524.txt | 0001193125-26-347524 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | — | awaiting T+5 | — | — |
Oct 15, 2026 11d ago | 8-K | $0.1100 $0.1200 | ▼ −9.09% | ▼ −9.52% | $0.1200 (−9.09%) |
Oct 6, 2026 20d ago | 25-NSE | $0.1400 $0.1400 | · 0.00% | ▼ −0.98% | $0.1200 (+14.29%) |
Aug 28, 2026 8w ago | 8-K | $0.1600 $0.1600 | · 0.00% | ▼ −0.14% | $0.1200 (+25.00%) |
Aug 12, 2026 10w ago | 8-K | $0.1700 $0.1602 | ▼ −5.76% | ▼ −3.80% | $0.1200 (−29.41%) |
Aug 12, 2026 10w ago | 8-K | $0.1700 $0.1602 | ▲ +5.76% | ▲ +3.80% | $0.1200 (+29.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers